# Phase 1/2 infections trials recruiting: 42 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials in phase 1/2 for infections that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 infections trials: 42 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/infections

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 42
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07888686 | Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV)... | Serum Institute of India Pvt. Ltd. | Phase 1/2 | Not yet recruiting | Human Papillomavirus Infection | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888686) |
| September 22, 2026 | NCT07832370 | A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD) | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Prion Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832370) |
| September 1, 2026 | NCT07797894 | Safety and Immunogenicity of HPV Vaccine in HIV-infected | Beijing 302 Hospital | Phase 1/2 | Not yet recruiting | HIV-infected Individuals | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797894) |
| June 26, 2026 | NCT07670468 | Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated... | LucasBio | Phase 1/2 | Recruiting | BKV Infection, EBV Infection, CMV Infection | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670468) |
| June 25, 2026 | NCT07668960 | Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade... | Shanghai Mianyi Biopharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668960) |
| June 10, 2026 | NCT07638332 | Evaluation of the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic... | LucasBio | Phase 1/2 | Not yet recruiting | Hemorrhagic Cystitis | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638332) |
| May 22, 2026 | NCT07600983 | Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | CanSino Biologics Inc. | Phase 1/2 | Recruiting | Streptococcus Pneumoniae Infection | 854 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07600983) |
| May 13, 2026 | NCT07582796 | Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. | Ab&B Bio-tech Co., Ltd.JS | Phase 1/2 | Recruiting | Respiratory Syncytial Virus Infections | 470 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582796) |
| May 12, 2026 | NCT07579741 | A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders | Jecho Biopharmaceuticals Co., Ltd. | Phase 1/2 | Recruiting | HIV Infections | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579741) |
| May 12, 2026 | NCT07579247 | Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS | Shanghai Public Health Clinical Center | Phase 1/2 | Not yet recruiting | HIV, AIDS, Immune Checkpoint Inhibitors, Refractory Opportunistic Infection | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579247) |
| May 11, 2026 | NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | Abramson Cancer Center at Penn Medicine | Phase 1/2 | Not yet recruiting | HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578467) |
| March 10, 2026 | NCT07462767 | Precision Microbiota Interventions for Senoreduction Trial | Louisiana State University Health Sciences Center in New Orleans | Phase 1/2 | Recruiting | HIV Infections, Alcohol Drinking, Aging, Immunosenescence | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462767) |
| January 26, 2026 | NCT07368634 | Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Epstein-Barr Virus Infection, Post-Transplant Lymphoproliferative Disorder | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07368634) |
| December 10, 2025 | NCT07275606 | A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1 | ViiV Healthcare | Phase 1/2 | Recruiting | HIV Infections | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07275606) |
| August 21, 2025 | NCT07133776 | Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases. | The Affiliated Hospital of Xuzhou Medical University | Phase 1/2 | Not yet recruiting | Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide, Lenalidomide | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07133776) |
| August 6, 2025 | NCT07106580 | Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Via Capsules for Intestinal Multidrug-resistant Bacteria Decolonization | University of Rijeka | Phase 1/2 | Recruiting | Colonization, Asymptomatic | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07106580) |
| June 22, 2025 | NCT07031999 | Use of Biocompatible Thermoplastic Impregnated With Vancomycin as a Temporary Orthopedic Spacer | Hospital Universitario Evangelico de Curitiba | Phase 1/2 | Not yet recruiting | Implant Failure, Infection | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07031999) |
| April 22, 2025 | NCT06938867 | Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001... | SNIPR Biome Aps. | Phase 1/2 | Recruiting | E Coli Infections, Allogenic Transplant Patients | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06938867) |
| April 18, 2025 | NCT06933238 | Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis | Dongzhimen Hospital, Beijing | Phase 1/2 | Not yet recruiting | Sepsis Abdominal, Gastrointestinal Dysfunction, Traditional Chinese Medicine | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06933238) |
| April 3, 2025 | NCT06909110 | Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06909110) |
| March 25, 2025 | NCT06892951 | CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia | University Hospital, Tours | Phase 1/2 | Recruiting | Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06892951) |
| February 6, 2025 | NCT06810934 | A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune... | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | COVID-19, SARS-CoV-2 Infection | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06810934) |
| January 29, 2025 | NCT06797986 | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | Cellid Co., Ltd. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma, HPV Positive... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06797986) |
| November 12, 2024 | NCT06684379 | Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory... | PEACHES BIOTECH | Phase 1/2 | Recruiting | SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome, Systemic... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06684379) |
| November 4, 2024 | NCT06672653 | Tolerance and Effectiveness of C14 on HPV Infection | MGB Pharma | Phase 1/2 | Not yet recruiting | HPV-induced Cancers, HPV Infections, HIV, Cervical Cancers, Trial, C14, Monoterpenoid Zinc Tetra-ascorbo-camphorate | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06672653) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| LucasBio | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| [ViiV Healthcare](https://specstream.ai/data/clinical-trials/company/viiv-healthcare) | 2 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2 |
| Gylden Pharma Ltd | 1 |
| All Natural Medicine Clinic, LLC | 1 |
| Blue Lake Biotechnology Inc. | 1 |
| University Hospital, Tours | 1 |
| Dongzhimen Hospital, Beijing | 1 |
| Shanghai Mianyi Biopharmaceutical Co., Ltd. | 1 |
| University Hospital, Basel, Switzerland | 1 |
| Hospital Universitario Evangelico de Curitiba | 1 |
| [CanSino Biologics Inc.](https://specstream.ai/data/clinical-trials/company/cansino-biologics-inc) | 1 |
| University of Rijeka | 1 |
| Nationwide Children's Hospital | 1 |
| Oregon Health and Science University | 1 |
| Louisiana State University Health Sciences Center in New Orleans | 1 |
| Beijing 302 Hospital | 1 |
| Cellid Co., Ltd. | 1 |
| University of California, San Diego | 1 |
| Jecho Biopharmaceuticals Co., Ltd. | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Marengo Therapeutics, Inc. | 1 |
| MGB Pharma | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 15 |
| China | 8 |
| France | 4 |
| South Korea | 3 |
| South Africa | 2 |
| Italy | 2 |
| Spain | 2 |
| Philippines | 1 |
| Argentina | 1 |
| Brazil | 1 |
| Haiti | 1 |
| Kenya | 1 |
| Malawi | 1 |
| Puerto Rico | 1 |
| Tanzania | 1 |
| Thailand | 1 |
| Uganda | 1 |
| Zambia | 1 |
| Zimbabwe | 1 |
| Switzerland | 1 |
| Croatia | 1 |
| Canada | 1 |
| Democratic Republic of the Congo | 1 |
| Australia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
- [Office supply stores in the United States](https://specstream.ai/data/businesses/office-supply-stores/united-states)
- [Shutters companies in the United States](https://specstream.ai/data/businesses/shutters-companies/united-states)
- [Aesthetic medicine clinics in the United States](https://specstream.ai/data/businesses/aesthetic-medicine-clinics/united-states)
- [Carpet cleaning companies in the United States](https://specstream.ai/data/businesses/carpet-cleaning-companies/united-states)
- [Farm insurance companies in the United States](https://specstream.ai/data/businesses/farm-insurance-companies/united-states)
